초록

• 전국단위 네트워크 구축
• 수집된 균주를 이용한 혈청형 분포 조사
• 부산, 경남 지역의 폐렴구균 항균제 내성 현황 파악
• 폐렴구균 혈청형 분석을 위한 표준화된 유전자형 분석법 고안
• 폐렴구균 감염증 환자의 균주 수집 및 임상정보 특성 분석
• 수집된 폐렴구균 균주의 혈청형 분석
• 수집된 폐렴구균 균주의 항균제 내성 현황 파악
• 폐렴구균 감염관련 역학 지표 산출
• 백신의 유용성 평가

(출처 : 보고서 요약서 3p)

Abstract ▼

Purpose & Contents
• Establish nationwide network for collection of Streptococcus pneumoniae
• Investigation of serotype distribtion using collected S. pneumoniae strains
• Investigation of antimicrobila resistance of S. pneumoniae in Busan and Gyeongnam
• Development of standardized gen

Purpose & Contents
• Establish nationwide network for collection of Streptococcus pneumoniae
• Investigation of serotype distribtion using collected S. pneumoniae strains
• Investigation of antimicrobila resistance of S. pneumoniae in Busan and Gyeongnam
• Development of standardized genotyping for serotyping of S. pneumoniae
• Collection of S. pneumoniae strains and clinical information
• Serotyping of collected S. pneumoniae strains
• Investigation of epidemiological index associated with S. pneumoniae infection
• Clinical evaluation of S. pneumoniae vaccine

Results
• Establish nationwide network for collection of Streptococcus pneumoniae
- We collected S. pneumoniae strains from 43 of 57 network hospitals
• Investigation of serotype distribtion using collected S. pneumoniae strains
- We performed serotyping of S. pneumoniae isoated during 2008 and 2014
- The most prevalenct serotypes are 3(13.5%) and followed by 35(10.8%), 19A(9.0%), 19F(6.6%), 6A(6.1%), 34 (5.6%)
- The resistatn rates to penicillin, cefotaxime, ceftriaxone, and levofloxacin isolated during 2008 and 2014were 9.0%, 4.1%, 4.7%, and 7.2%, respectively.
• Investigation of antimicrobila resistance of S. pneumoniae in Busan and Gyeongnam
- We found quite differences of antimicrobial resistance among 4 Universtiy hospitals.
- The resistant rates to penicillin, cefotaxime, and levofloxacin of S. pneumoniae were 8.3%, 8.21%, and 9.2% respectively .
- The resistant rates to penicillin, cefotaxime, ceftriaxone and levofloxacin of S. pneumoniae isolated during 2014 and 2016 were 22.8%, 12.5%, 12.0%, and 9.4% respectively.
• Development of standardized genotyping for serotyping of S. pneumoniae
- We developed new SM-PCR for serotyping form common serotypes in Asia
- We confirmed their clinilcal usefulness by comparing with Quellung test
• Collection of S. pneumoniae strains and clinical information
- We collected 1855 S. pneumoniae strains and analyzed their clinical characteristics during May 2014 and April 2016
- 248 (13.4%) of 1855 S. pneumoniae were isolated from children under 5 year old and the invasive isolates were 438 (23.6^) strains.
• Serotyping of collected S. pneumoniae strains
- The most common serotype was 11A (N=118, 10.1%) followed by 19A (N=163주, 8.8%), 3 (N=158, 8.5%), 34 (N=151, 8.1%), 23A (N=136, 7.3%), 35B (N=115, 6.2%)
- We confirmed the difference of serotype distribution according to the age and specimens.
• Investigation of epidemiological index associated with S. pneumoniae infection
- The trend is the decrease of invasive and noninvasive S. pneumoniae infection during 2011 and 2015, however, the prevalence of S. pneumoniae pneumoniae was quitely increased among less than 1 year children.
• Clinical evaluation of S. pneumoniae vaccine
- The prevalence of serotype of 7 and 10 polyvalent vaccine was similar, however, those of 13 polyvalent vaccine were 2.5 times higher. The prevalence of 13 vaccine serotypes were decreased and nonvaccine serotypes were sharply increased.

Expected Effect
• Use of constructed nationwide network for continuous collection of S. pneumoniae.
• Provide the base line data for domestic changes of serotyping of S. pneumoniae
• Provide the principla treatment guideline using the nationwide antimicrlbial susceptibility test restuls
• The new SM-PCR method would be useful to investigate the serotypes in Korea and Asia countires.
• The result of changes of serotyping distribution will give an important information for new vaccine of S. pneumoniae in the fulture

(출처 : SUMMARY 6p)

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 국문요약문 ... 4
• SUMMARY ... 6
• 목차 ... 8
• 1. 연구개발과제의 개요 ... 9
• 1-1. 연구개발 목적 ... 9
• 1-2. 연구개발의 필요성 ... 9
• 1-3. 연구개발 범위 ... 12
• 2. 국내외 기술개발 현황 ... 14
• 3. 연구수행 내용 및 결과 ... 16
• 1. 전국단위 네트워크 구축 ... 16
• 2. 폐렴구균 균주 수집 및 보관 ... 18
• 3. 연구 진행을 위한 IRB 심의 ... 19
• 4. 수집된 균주를 이용한 혈청형 분포 조사 ... 20
• 5. 부산, 경남 지역의 폐렴구균 항균제 내성 현황 파악 ... 27
• 6. 표준화된 유전형 분석법 고안 ... 30
• 7. 폐렴구균 감염증 환자의 균주 수집 및 보관 ... 39
• 8. 수집된 폐렴구균 균주의 혈청형 분석 ... 41
• 9. 수집된 폐렴구균 균주의 항균제 내성 현황 파악 ... 47
• 10. 폐렴구균 감염관련 역학 지표 산출 ... 50
• 11. 백신의 유용성 평가 ... 62
• 4. 목표달성도 및 관련분야 기여도 ... 68
• 4-1. 목표달성도 ... 68
• 5. 연구결과의 활용계획 ... 69
• 6. 연구과정에서 수집한 해외과학기술정보 ... 70
• 7. 연구개발성과의 보안등급 ... 70
• 8. 국가과학기술종합정보시스템에 등록한 연구시설·장비 현황 ... 70
• 9. 연구개발과제 수행에 따른 연구실 등의 안전조치 이행실적 ... 71
• 10. 연구개발과제의 대표적 연구실적 ... 74
• 11. 기타사항 ... 74
• 12. 참고문헌 ... 75
• 별첨 ... 77
• 끝페이지 ... 81